Abstract:Background The neuropathological hallmarks of Alzheimer’s disease (AD) are amyloid-β (Aβ) plaques and neurofibrillary tangles (NFTs). The amyloid cascade theory is the leading hypothesis of AD pathology. Aβ deposition precedes the aggregation of tau pathology and Aβ pathology precipitates tau pathology. Evidence also indicates the reciprocal interactions between amyloid and tau pathology. However, the detailed relationship between amyloid and tau pathology in AD remains elusive. Metformin might have a positive effect on cognitive impairments. However, whether metformin can reduce AD-related pathologies is still unconclusive. Methods Brain extracts containing tau aggregates were unilaterally injected into the hippocampus and the overlying cerebral cortex of 9-month-old APPswe/PS1DE9 (APP/PS1) mice and age-matched wild-type (WT) mice. Metformin was administrated in the drinking water for 2 months. Aβ pathology, tau pathology, plaque-associated microgliosis, and autophagy marker were analyzed by immunohistochemical staining and immunofluorescence analysis 2 months after injection of proteopathic tau seeds. The effects of metformin on both pathologies were explored. Results We observed tau aggregates in dystrophic neurites surrounding Aβ plaques (NP tau) in the bilateral hippocampi and cortices of tau-injected APP/PS1 mice but not WT mice. Aβ plaques promoted the aggregation of NP tau pathology. Injection of proteopathic tau seeds exacerbated Aβ deposits and decreased the number of microglia around Aβ plaques in the hippocampus and cortex of APP/PS1 mice. Metformin ameliorated the microglial autophagy impairment, increased the number of microglia around Aβ plaques, promoted the phagocytosis of NP tau, and reduced Aβ load and NP tau pathology in APP/PS1 mice. Conclusion These findings indicate the existence of the crosstalk between amyloid and NP tau pathology. Metformin promoted the phagocytosis of pathological Aβ and tau proteins by enhancing microglial autophagy capability. It reduced Aβ deposits and limited the spreading of NP tau pathology in APP/PS1 mice, which exerts a beneficial effect on both pathologies.

Metformin acts directly in the brain to slow features of neurodegeneration

Metformin Improves Cognition of Aged Mice by Promoting Cerebral Angiogenesis and Neurogenesis

Metformin Alters Locomotor and Cognitive Function and Brain Metabolism in Normoglycemic Mice.

Metformin Attenuates Tau Pathology in Tau-Seeded PS19 Mice.

Metformin Attenuates Plaque-Associated Tau Pathology and Reduces Amyloid-Β Burden in APP/PS1 Mice

Metformin as a potential therapeutic for neurological disease: mobilizing AMPK to repair the nervous system

Metformin Treatment Attenuates Tau Seeding in Neuritic Plaques

Metformin Protects Against Diabetes-Induced Cognitive Dysfunction by Inhibiting Mitochondrial Fission Protein DRP1.

Metformin mitigates amyloid β1-40-induced cognitive decline via attenuation of oxidative/nitrosative stress and neuroinflammation

Exploring the Pharmacological Potential of Metformin for Neurodegenerative Diseases

Reconsidering repurposing: long-term metformin treatment impairs cognition in Alzheimer's model mice

Metformin improves cognitive dysfunction through SIRT1/NLRP3 pathway-mediated neuroinflammation in db/db mice

Antioxidant and Anti-Senescence Effect of Metformin on Mouse Olfactory Ensheathing Cells (mOECs) May Be Associated with Increased Brain-Derived Neurotrophic Factor Levels—An Ex Vivo Study

Metformin Attenuates Alzheimer's Disease-Like Neuropathology in Obese, Leptin-Resistant Mice

Metformin Mitigates Trimethyltin-Induced Cognition Impairment and Hippocampal Neurodegeneration

Metformin Promotes Tau Aggregation and Exacerbates Abnormal Behavior in a Mouse Model of Tauopathy

Novel targets and therapies of metformin in dementia: old drug, new insights

Metformin Protects PC12 Cells and Hippocampal Neurons from H2O2‐induced Oxidative Damage Through Activation of AMPK Pathway

Effects of chronic treatment with metformin on brain glucose hypometabolism and central insulin actions in transgenic mice with tauopathy

Repurposing metformin to treat age-related neurodegenerative disorders and ischemic stroke

Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?